Hutchinson (Fred) Cancer Research Center

Funding Organization

Awards Grant

  • Apoptosis of HIV Vaccine Elicited B Responses as a Marker of Vaccine Durability
  • COVID-19 Prevention Network (CoVPN) Site Preparation Funding - Birmingham Clinical Research Site
  • Clincial Research Site Activities for the LTE to HVTN 117/HPX2004
  • CoVPN 3002 Protocol Funding (PF)
  • CoVPN 3003 Protocol Funding (PF)
  • CoVPN 3006 Protocol Funding (PF) - Birmingham Clinical Research Site
  • CoVPN 5001 (Acute Immune Responses to SARS-CoV-2 Infection) Protocol Funding (PF)
  • Dexrazoxane and Prevention of Anthracycline Related Cardiotoxicity
  • Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
  • HIV Vaccine Trials Network Correlates Protocol Funding
  • HIV Vaccine Trials Network P5 Program Protocol Funding: HVTN 111
  • HPX3002/HVTN 706 Protocol Funding (PF)
  • HVTN Protocol Funding Year 14
  • HVTN 405/HPTN 1901 Protocol Funding (PF) - Birmingham Clinical Research Site
  • HVTN 505 Protocol Implementation Funds
  • HVTN 703/HPTN 081 Protocol Funding (PF)
  • HVTN 703/HPTN 081 Site Readiness
  • HVTN 704/HPTN 085 Protocol Funding (PF)
  • HVTN 704/HPTN 085 Protocol Funding (PF) - Birmingham Clinical Research Site
  • HVTN 705 Protocol Funds
  • HVTN Initiatives Program (HIP)
  • HVTN Protocol Funding (PF)
  • HVTN Protocol Funding (PF)
  • HVTN Protocol Funding (PF)
  • HVTN Protocol Funding (Pf): Birmingham Clinical Research Site
  • HVTN Protocol Funding Year 13
  • HVTN Protocol Implementation Funds
  • HVTN Research and Mentorship Program (RAMP)
  • HVTN Research and Mentorship Program (RAMP)
  • HvTN Scientific Leadership - Co-Chair, Concept Working Group
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 117/118
  • NIAID-Fred Hutch-Janssen Collaboration CTU/Clinical Trial Site Activities for HVTN 118/HPX2003 - Birmingham Clinical Research Site
  • Objective Physical Activity and Cardiovascular Health in Women Aged 80 and Older (OPACH80)
  • Therapeutic Use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial
  • XUAB 2069: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm